Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.

[1]  A. Brandes,et al.  Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial. , 2019, JACC. Heart failure.

[2]  R. Porcher,et al.  Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. , 2019, Circulation.

[3]  George A. Johnson,et al.  Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. , 2018, JACC. Clinical electrophysiology.

[4]  K. Swedberg,et al.  Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. , 2017, Journal of the American College of Cardiology.

[5]  C. O'connor,et al.  Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? , 2017, JACC. Clinical electrophysiology.

[6]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[7]  D. Mozaffarian,et al.  A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. , 2015, Heart rhythm.

[8]  Mark A Hlatky,et al.  2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2013, Circulation.

[9]  U. Dahlström,et al.  Heart failure registry: a valuable tool for improving the management of patients with heart failure , 2010, European journal of heart failure.

[10]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[11]  D. Mozaffarian,et al.  Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population , 2009, Circulation.

[12]  A. di Lenarda,et al.  [Italian Network on Congestive Heart Failure: ten-year experience]. , 2006, Giornale italiano di cardiologia.

[13]  P. Poole‐Wilson,et al.  A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). , 2006, Journal of the American College of Cardiology.

[14]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[15]  J. Spertus,et al.  Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. , 2004, The American journal of cardiology.

[16]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[17]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[18]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[19]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.